PLA2R1

Secretory phospholipase A2 receptor · Q13018 · PLA2R1 on Sugi Atlas →

45 patent compounds predicted against PLA2R1, 35 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Macrocarpal B (SCHEMBL96058)	1.00	1/20
Macrocarpal A (SCHEMBL96208)	1.00	1/20
Macrocarpal A (SCHEMBL96222)	1.00	1/20
Macrocarpal A (SCHEMBL4412279)	1.00	1/20
Macrocarpal A (SCHEMBL4413981)	1.00	1/20
Macrocarpal A (SCHEMBL13597677)	1.00	1/20
Macrocarpal A (SCHEMBL13597681)	1.00	1/20
Macrocarpal A (SCHEMBL23484425)	1.00	1/20
Macrocarpal A (SCHEMBL27602003)	1.00	1/20
SCHEMBL12549605	0.83	1/20
SCHEMBL12549608	0.83	1/20
SCHEMBL31432951	0.76	1/20
SCHEMBL96376	0.71	1/20
Macrocarpal C (SCHEMBL96125)	0.68	1/20
Macrocarpal C (SCHEMBL136282)	0.68	1/20
Macrocarpal C (SCHEMBL4411392)	0.68	1/20
Macrocarpal C (SCHEMBL4419114)	0.68	1/20
Macrocarpal C (SCHEMBL23484420)	0.68	1/20
SCHEMBL2885029	0.60	1/20
SCHEMBL2885673	0.60	1/20

Clinical trials — most relevant to PLA2R1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
Pharmacogenomics of Antiplatelet Response - I	PHASE4	COMPLETED
Adrenocorticotropic Hormone in Membranous Nephropathy	PHASE4	COMPLETED
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis	PHASE3	COMPLETED
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy	PHASE3	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM	PHASE3	COMPLETED
Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy	PHASE3	UNKNOWN
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study	PHASE2/PHASE3	RECRUITING
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)	PHASE1/PHASE2	COMPLETED
Fish Oil and Aspirin With Type 2 Diabetes	PHASE2	COMPLETED
DHA For The Treatment of Pediatric Concussion Related to Sports Injury	PHASE1	COMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling	nan	COMPLETED
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy	nan	COMPLETED
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy	nan	COMPLETED
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy	nan	COMPLETED
Mucomyst for Hepatitis C	nan	SUSPENDED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy	nan	COMPLETED
An Outcome Analysis of Primary Membranous Nephropathy	nan	RECRUITING
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke	nan	COMPLETED
Clinical Trial of Anti-PLA2R-IgG Detection Kit (Time-resolved Fluorescence Immunoassay)	nan	COMPLETED
Local Anaesthetic and Steroid in the Ureter	nan	UNKNOWN
Thrombin Regulated Platelet Activation	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy	nan	UNKNOWN
PET Imaging of DHA Metabolism	nan	COMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING
A Real World Study About PMN	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PLA2R1 binder may also engage these)

Protein	Name	Similarity
Q5R880	—	1.000	Q5R880 →
P49260	—	1.000	P49260 →
P49259	—	1.000	P49259 →
Q62028	—	0.996	Q62028 →
Q60767	—	0.993	Q60767 →
O60449	—	0.991	O60449 →
Q920P9	—	0.987	Q920P9 →
Q9QWJ9	—	0.973	Q9QWJ9 →
P30836	—	0.972	P30836 →
P23132	—	0.971	P23132 →
Q9Y5Q5	—	0.971	Q9Y5Q5 →
P97333	—	0.971	P97333 →
SELL	L-selectin	0.970	landscape →
Q95237	—	0.970	Q95237 →
A3FM55	—	0.970	A3FM55 →
P98131	—	0.969	P98131 →
Q3LUH2	—	0.969	Q3LUH2 →
Q9EPW4	—	0.968	Q9EPW4 →
P27113	—	0.968	P27113 →
NRP1	Neuropilin-1	0.968	landscape →
P14371	—	0.968	P14371 →
Q9Z2H6	—	0.968	Q9Z2H6 →
Q61830	—	0.967	Q61830 →
Q6EIG7	—	0.967	Q6EIG7 →
Q92778	—	0.967	Q92778 →
C0HKZ6	—	0.966	C0HKZ6 →
D2YW39	—	0.966	D2YW39 →
F1QVU0	—	0.966	F1QVU0 →
Q8WTT0	—	0.966	Q8WTT0 →
Q9DEA2	—	0.966	Q9DEA2 →